Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Free Cash Flow (2020 - 2025)

Barinthus Biotherapeutics' Free Cash Flow history spans 6 years, with the latest figure at -$4.2 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 133.12% year-over-year to -$4.2 million; the TTM value through Dec 2025 reached -$48.0 million, down 60.95%, while the annual FY2025 figure was -$48.0 million, 60.95% down from the prior year.
  • Free Cash Flow reached -$4.2 million in Q4 2025 per BRNS's latest filing, up from -$10.7 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $14.8 million in Q3 2022 to a low of -$19.4 million in Q4 2023.
  • Average Free Cash Flow over 5 years is -$9.4 million, with a median of -$11.4 million recorded in 2024.
  • Peak YoY movement for Free Cash Flow: tumbled 606.49% in 2021, then surged 642.53% in 2022.
  • A 5-year view of Free Cash Flow shows it stood at -$8.4 million in 2021, then crashed by 105.6% to -$17.3 million in 2022, then dropped by 12.68% to -$19.4 million in 2023, then skyrocketed by 165.85% to $12.8 million in 2024, then plummeted by 133.12% to -$4.2 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Free Cash Flow are -$4.2 million (Q4 2025), -$10.7 million (Q3 2025), and -$18.1 million (Q2 2025).